Cargando…
Clinical experience with tigecycline in the treatment of hospital-acquired pneumonia caused by multidrug resistant Acinetobacter baumannii
BACKGROUND: Tigecycline, with broad in vitro antibacterial activity, has been widely used off-label for nosocomial pneumonia caused by multi-drug resistant Acinetobacter baumannii (MDRAB). However, many concerns have been raised about the efficacy of tigecycline treatment as the inconsistent results...
Autores principales: | Zhou, Yangang, Chen, Xumin, Xu, Ping, Zhu, Yan, Wang, Kuangguo, Xiang, Daxiong, Wang, Feng, Banh, Hoan Linh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6482491/ https://www.ncbi.nlm.nih.gov/pubmed/31023357 http://dx.doi.org/10.1186/s40360-019-0300-3 |
Ejemplares similares
-
Outcomes and prognostic factors of tigecycline treatment for hospital-acquired pneumonia involving multidrug-resistant Acinetobacter baumannii
por: Liu, Ben, et al.
Publicado: (2020) -
Sulbactam combined with tigecycline improves outcomes in patients with severe multidrug-resistant Acinetobacter baumannii pneumonia
por: Deng, Yanling, et al.
Publicado: (2022) -
Polymyxin B, Cefoperazone Sodium-Sulbactam Sodium, and Tigecycline against Multidrug-Resistant Acinetobacter baumannii Pneumonia
por: Hu, Guangxue, et al.
Publicado: (2022) -
Clinical Outcomes of Tigecycline in the Treatment of Multidrug-Resistant Acinetobacter baumannii Infection
por: Shin, Jung Ar, et al.
Publicado: (2012) -
High-Dose Tigecycline in Elderly Patients with Pneumonia Due to Multidrug-Resistant Acinetobacter baumannii in Intensive Care Unit
por: Bai, Xiang-Rong, et al.
Publicado: (2020)